Correction of defective tumoricidal activity of macrophages from A/J mice by liposomal immunomodulators.
The ability of liposomal immunomodulators to restore abnormal macrophage tumoricidal activity has been studied. Macrophages from A/J mice have impaired responses in vitro to macrophage activating factor, gamma-interferon, N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) or lipopolysaccharide when compared with macrophages from normoresponsive C57BL/6J mice. Liposomes containing a lipophilic muramyl dipeptide MDP-glyceroyl dipalmitate, macrophage activating factor or gamma-interferon restored tumoricidal activity to levels similar to C57BL/6J macrophages. Pretreatment of A/J mice with Corynebacterium parvum resulted in low levels of macrophage tumoricidal activity: treatment of C. parvum-induced A/J macrophages in vivo or in vitro with liposomal MDP-glyceroyl dipalmitate or liposomal macrophage activating factor resulted in normal levels of cytotoxicity. Macrophages from A/J mice were unable to phagocytose liposomes in vitro as rapidly or to the same extent as macrophages from C57BL/6J mice. The levels of cytotoxicity observed indicate that this is not a limiting factor for the induction of tumoricidal activity by liposomal immunomodulators.[1]References
- Correction of defective tumoricidal activity of macrophages from A/J mice by liposomal immunomodulators. Phillips, N.C., Skamene, E., Chedid, L. Immunopharmacology (1988) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
